CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-26 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −13,000 | 12,740 | ||
| 2024-01-09 | Kersten Dirk Director | Purchase | +285,714 | $17.50 | $5.0M | 6,416,793 |
| 2024-01-09 | Kersten Dirk Director | Purchase | +1,428,571 | $17.50 | $25.0M | 1,428,571 |
| 2024-01-04 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +18,536 | $1.03 | $19K | 603,507 |
| 2024-01-04 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +200,000 | $5.54 | $1.1M | 803,507 |
| 2024-01-04 | Brumm Joshua T CEO & President | Sale 10b5-1 | −180,235 | $18.40 | $3.3M | 623,272 |
| 2024-01-04 | Brumm Joshua T CEO & President | Sale 10b5-1 | −38,301 | $19.05 | $730K | 584,971 |
| 2024-01-04 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −18,536 | 0 | ||
| 2024-01-04 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −200,000 | 107,863 | ||
| 2024-01-04 | Beskrovnaya Oxana Chief Scientific Officer | Option exercise 10b5-1 | +22,674 | $1.03 | $23K | 199,259 |
| 2024-01-04 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −42,453 | $18.13 | $770K | 156,806 |
| 2024-01-04 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +2,009 | $0.73 | $1K | 145,627 |
| 2024-01-04 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −2,009 | $18.04 | $36K | 143,618 |
| 2024-01-04 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −2,009 | 48,528 | ||
| 2024-01-03 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +51,183 | $1.03 | $53K | 636,154 |
| 2024-01-03 | Brumm Joshua T CEO & President | Sale 10b5-1 | −15,382 | $18.34 | $282K | 620,772 |
| 2024-01-03 | Brumm Joshua T CEO & President | Sale 10b5-1 | −19,775 | $19.03 | $376K | 600,997 |
| 2024-01-03 | Brumm Joshua T CEO & President | Sale 10b5-1 | −16,026 | $20.50 | $329K | 584,971 |
| 2024-01-03 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −51,183 | 18,536 | ||
| 2024-01-03 | Beskrovnaya Oxana Chief Scientific Officer | Option exercise 10b5-1 | +45,326 | $1.03 | $47K | 221,911 |
Page 27 of 29 · 561 trades